drug development

Biotech By Adam Feuerstein

New data on CRISPR Therapeutics’ off-the-shelf CAR-T cancer therapy shows more remissions, no major safety issues

In the Lab By Megan Molteni

Mouse experiments with a decades-old drug suggest a new approach to Alzheimer’s treatment

Biotech By Adam Feuerstein

Disappointing tumor responses, more side effects, seen with latest Amgen KRAS combination studies

Pharmalot By Ed Silverman

Older Americans bore the brunt of antibiotic-resistant infections, study finds

Health By Ed Silverman

Virtual Event: The evolving landscape for biosimilars

Health By Nicholas St. Fleur

STAT+ Conversation: Selling Cellarity

Biotech By Adam Feuerstein

Is a Beyondspring drug helping lung cancer patients live longer? Study results trigger debate

First Opinion By Peter Kolchinsky and Daphne Zohar

Congress is about to legislate a future without new medicines. We have a better plan

First Opinion By Emily Milligan and Katherine R. McCurdy

Aduhelm backlash threatens to reverse progress in FDA’s reviews of rare and ultra-rare disease drugs

Adam's Take By Adam Feuerstein

In new remarks, Cassava Sciences’ CEO shifts defense of embattled treatment for Alzheimer’s

Health Tech By Erin Brodwin

After a decade at Facebook and Google, a tech exec tries his hand at drug development

Pharmalot By Ed Silverman

Biogen trials for Alzheimer’s drug excluded much of the targeted patient pool, study finds

Biotech By Adam Feuerstein

The future of Apellis Pharma’s eye disease treatment is clouded by divergent study results

In the Lab By Peter Andrey Smith

In the hunt for novel antibiotics, will new technology overtake underwater exploration?

First Opinion By Armand Balboni

New antivirals are sorely needed. A public-private partnership can get us there

Exclusive By Kate Sheridan

Flagship, Orbimed, ARCH, Alta top list of high-performing biotech venture capital firms

Politics By Nicholas Florko

Ellis Unger, an outspoken FDA veteran, retires

Biotech By Damian Garde

Virtual Event: Gene therapy’s next steps

First Opinion By Keith Flanagan

Congress should fix FDA’s accelerated approval program for the next 30 years

Pharmalot By Ed Silverman and Damian Garde

Veterans Affairs declines to cover Biogen’s Alzheimer’s drug over effectiveness, safety concerns

Pharmalot By Ed Silverman

‘Things are so messed up’: Patient access to antibiotics is lacking even in the wealthiest countries

Health By Nicholas St. Fleur

STAT+ Conversation: Blueprint for cancer drugs

Politics By Nicholas Florko

Will controversy over new Alzheimer’s drug spell the end for the FDA’s faster approval process?

Pharmalot By Ed Silverman

After leaving patients in limbo, Pfizer agrees to sell a discontinued glaucoma drug

Politics By Lev Facher

Billions in new research funding sparks a lobbying frenzy among patient advocates